--Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors that target dysfunctional metabolic pathways, today announced the ...

FORMA’s FASN Inhibitor FT-4101 Significantly Reduced Hepatic De Novo Lipogenesis in Healthy Adult Subjects - Phase 1 data presented in a poster session at AASLD’s The Liver Meeting® 2019 - ...

Sagimet Biosciences cleared an IND for TVB-3567, a FASN inhibitor for acne, with Phase 1 trials planned for 2025. Quiver AI Summary. Sagimet Biosciences Inc. announced the clearance of its ...

Preclinical Characterization of BJT-188 . This study evaluated the intrinsic potency of BJT-188 versus denifanstat, an investigational FASN inhibitor, by measuring in vitro inhibition of de novo ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary ...

The data are being presented at the European Association for the Study of the Liver (EASL) Congress 2025 REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a clinical ...